Furthermore, ABC294640 up‐regulates Noxa expression and reduces the expression of Mcl‐1 and c‐Myc by inducing their proteasome degradation.4 ABC294640 effectively inhibited myeloma tumor growth in vivo in mouse xenograft models, and has recently completed a Phase I safety study where it demonstrated an excellent safety profile in solid tumors.27 Our group has recently started a phase I/II clinical trial with single agent ABC294640 in relapsed and refractory multiple myeloma patients (clinicaltrials.gov: #NCT01410981). This evidence concerns the gene MCL1 and plasma cell myeloma.